menu
    • menu
    [{"orgOrder":0,"company":"NanoMab Technology","sponsor":"OncoBeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2020","type":"Agreement","leadProduct":"188-Re","moa":"Beta-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab Technology \/ NanoMab Technology","highestDevelopmentStatusID":"1","companyTruncated":"NanoMab Technology \/ NanoMab Technology"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"NanoMab Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"99m-Tc NM-02","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoMab Technology \/ NanoMab Technology","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ NanoMab Technology"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab Technology \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ University Hospital Aachen"}]

    Find Clinical Drug Pipeline Developments & Deals by NanoMab Technology

    Menu

    NanoMab Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NanoMab Technology

                            China arrow
                            FNCE
                            Not Confirmed

                            NanoMab Technology

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc NM-02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Shanghai General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain An...

                            Details : 99m-Tc NM-02 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 19, 2020

                            Lead Product(s) : 99m-Tc NM-02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Shanghai General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NanoMab Technology

                            China arrow
                            FNCE
                            Not Confirmed

                            NanoMab Technology

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 188-Re

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : OncoBeta

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NanoMab and OncoBeta Outline the Pathway to a Strategic Alliance and Supply Agreement Focused on the Secure Su...

                            Details : The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            October 27, 2020

                            Lead Product(s) : 188-Re

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : OncoBeta

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NanoMab Technology

                            China arrow
                            FNCE
                            Not Confirmed

                            NanoMab Technology

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM-02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University Hospital Aachen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NanoMab and University Hospital Aachen to Start a Cancer Therapy Programme utilising next generation NM-02 rad...

                            Details : The programme will utilise Nanomab’s next generation NM-02 radiopharmaceutical product targeting a First in Human (FIH) administration to develop novel radiopharmaceutical product for patients with HER2 positive breast cancer.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 21, 2020

                            Lead Product(s) : NM-02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University Hospital Aachen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth